1. Paxlovid 150 mg + 100 mg film-coated tablets Summary of Product Characteristics [cited 21.04.2023]. Available from URL: https://www.ema.europa.eu/en/documents/product-information/paxlovid-epar-product-information_en.pdf.
2.
European Medicines Agency Paxlovid Authorisation details [cited 09.05.2023.] Available from URL: https://www.ema.europa.eu/en/medicines/human/EPAR/paxlovid.
3.
Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med 2022; 386(15): 1397–1408.
4.
Lewnard JA, McLaughlin JM, Malden D, et al. Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system. Lancet Infect Dis 2023; 23(7): 806–815.
5.
Marzi M, Vakil MK, Bahmanyar M, et al. Paxlovid: Mechanism of Action, Synthesis, and In Silico Study. Biomed Res Int 2022; 2022: 7341493, doi: 10.1155/2022/7341493.
6.
Stockley’s Drug Interactions: Medicines Complete online platform [cited 09.05.2023]. Available from URL: https://about.medicinescomplete.com/publication/stockleys-drug-interactions/.
7.
Lexicomp Drug Interactions [cited 09.05.2023]. Available from URL: https://www.wolterskluwer.com/en/solutions/lexicomp/resources/lexicomp-user-academy/drug-interactions-analysis.
8.
Medscape Drug Interaction Checker [cited 09.05.2023]. Available from URL: https://reference.medscape.com/drug-interactionchecker.
9.
Kongsholm GG, Nielsen AKT, Damkier P. Drug interaction databases in medical literature: transparency of ownership, funding, classification algorithms, level of documentation, and staff qualifications. A systematic review. Eur J Clin Pharmacol 2015; 71(11): 1397–1402.
10.
Shini Rubina SK, Pharm D, Anuba PA, et al. Drug interaction risk between cardioprotective drugs and drugs used in treatment of COVID-19: a evidence-based review from six databases. Diabetes Metab Syndr 2022; 16(3): 102451.
11.
Tornio A, Filppula AM, Niemi M, et al. Clinical Studies on Drug-Drug Interactions Involving Metabolism and Transport: Methodology, Pitfalls, and Interpretation. Clin Pharmacol Ther 2019; 105(6): 1345–1361.
12.
Roberts AG, Gibbs ME. Mechanisms and the clinical relevance of complex drug-drug interactions. Clin Pharmacol 2018; 10: 123–34.
13.
Zhao M, Ma J, Li M, et al. Cytochrome P450 Enzymes and Drug Metabolism in Humans. Int J Mol Sci 2021; 22(23): 12808, doi: 10.3390/ijms222312808.
14.
U.S. Food and drug administration. Drug Development and Drug Interactions. Table of Substrates, Inhibitors and Inducers [cited 22.04.2023]. Available from URL: https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers.
15.
Flockhart DA, Thacker D, McDonald C, et al. The Flockhart Cytochrome P450 Drug-Drug Interaction Table. Division of Clinical Pharmacology, Indiana University School of Medicine (Updated 2021) [cited 22.04.2023]. Available from URL: https://drug-interactions.medicine.iu.edu.
16.
Gerhard Nahler. Dictionary of Pharmaceutical Medicine. Cham: Springer International Publishing AG, 2017 [cited 15.05.2023]. Available from: ProQuest Ebook Central.
17.
Boffito M, Back D, Gatell JM. Twenty years of boosting antiretroviral agents: where are we today? AIDS 2015; 29(17): 2229–2233.
18.
National Institutes of Health Coronavirus Disease 2019 (COVID-19) Treatment guidelines. Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications [cited 03.05.2023]. Available from URL: https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/ritonavir-boosted-nirmatrelvir--paxlovid-/paxlovid-drug-drug-interactions/.
19.
Marzolini C, Kuritzkes DR, Marra F, et al. Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications. Clin Pharmacol Ther 2022; 112(6): 1191–1200.
20.
Lemaitre F, Grégoire M, Monchaud C, et al. Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT). Therapie 2022; 77(5): 509–521.
21.
University of Liverpool COVID-19 Drug interaction database [cited 29.04.2023]. Available from URL: https://www.covid19-druginteractions.org/.
22.
EU Risk management plan for Paxlovid (PF-07321332/Ritonavir): Date of final sign off: 01 September 2022 [cited 21.04.2023]. Available from URL: https://www.ema.europa.eu/en/documents/rmp-summary/paxlovid-epar-risk-management-plan_en.pdf.
23.
Stader F, Kinvig H, Battegay M, et al. Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications. Antimicrob Agents Chemother 2018; 62(7): e00717-18, doi: 10.1128/AAC.00717-18.
24.
Abraham S, Nohria A, Neilan TG, et al. Cardiovascular Drug Interactions with Nirmatrelvir/Ritonavir in Patients with COVID-19: JACC Review Topic of the Week. J Am Coll Cardiol 2022; 80(20): 1912–1924.
25.
Katzenmaier S, Markert C, Riedel K-D, et al. Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy. Clin Pharmacol Ther 2011; 90(5): 666–673.
26.
Loos NHC, Beijnen JH, Schinkel AH. The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins. Biomed Pharmacother 2023; 162: 114636.
27.
Stader F, Khoo S, Stoeckle M, et al. Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug inter-acting effect. J Antimicrob Chemother 2020; 75(10): 3084–3086.
28.
Aarnoutse RE, Kleinnijenhuis J, Koopmans PP, et al. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers. Clin Pharmacol Ther 2005; 78(6): 664–674.
29.
Cattaneo D, Cossu MV, Rizzardini G. Pharmacokinetic drug evaluation of ritonavir (versus cobicistat) as adjunctive therapy in the treatment of HIV. Expert Opin Drug Metab Toxicol 2019; 15(11): 927–935.
30.
Sinthrome 1 mg Tablets Summary of Product Characteristics [cited 06.05.2023]. Available from URL: https://www.medicines.org.uk/emc/product/2058/smpc#gref.
31.
Wanounou M, Caraco Y, Levy RH, et al. Clinically Relevant Interactions Between Ritonavir-Boosted Nirmatrelvir and Concomitant Antiseizure Medications: Implications for the Management of COVID-19 in Patients with Epilepsy. Clin Pharmacokinet 2022; 61(9): 1219–1236.
32.
Sluijters A, Lemaitre F, Belkhir L, et al. A Case Report of Safe Coadministration of Amiodarone with Short-Term Treatment Nirmatrelvir-Ritonavir. Clin Pharmacol Ther 2023; 113(4): 768–769.
33.
Lange NW, Salerno DM, Jennings DL, et al. Nirmatrelvir/ritonavir use: Managing clinically significant drug-drug inter-actions with transplant immunosuppressants. Am J Transplant 2022; 22(7): 1925–1926.
34.
Tang Y, Li Y, Song T. Optimizing the use of nirmatrelvir/ritonavir in solid organ transplant recipients with COVID-19: A review of immunosuppressant adjustment strategies. Front Immunol 2023; 14: 1150341.
35.
Vazquez SR, Wilson AS, Witt DM. Management of potential drug-drug interactions with nirmatrelvir-ritonavir and oral anticoagulants: a case series. J Thromb Thrombolysis 2022; 54(4): 583–586.
36.
European Medicines Agency (EMA) List of medicinal products under additional monitoring. [cited 06.05.2023]. Available from URL: https://www.ema.europa.eu/en/documents/additional-monitoring/list-medicinal-products-under-additional-monitoring_en.pdf.
